MDB Capital Group

Helping meaningful technologies get to market.

MDB Capital Group LLC

Preventing and intercepting auto-immune disease.

ProventionBio | $64 Million | Intial Public Offering | July 2018

Delivering precision therapeutics for immuno-oncology & autoimmunity

Cue Biopharma, Inc. | $66 Million | Intial Public Offering | Jan 2018

Cell signalling to treat unmet medical needs.

Pulse Biosciences | $23 Million | Initial Public Offering | June 2016

Restoring vision to people who are blind.

Second Sight | $36 Million | Initial Public Offering | November 2014

Bringing wireless power to the people.

Energous Corporation | $27.6 Million | Initial Public Offering | March 2014

MDB Capital Group finances development stage companies that possess meaningful technology that has the potential to impact large commercial markets and benefit humanity. MDB maximizes the value of these technology companies by helping position them to be the dominant leader in their technology domain and connecting them with a base of high-quality investors.

The Road Ahead for MDB >

A Blueprint for Funding Billion-Dollar Companies in Energy.

Do venture capitalists get it wrong when investing in disruptive technologies?

View Article >